Mahidol University has launched Chimeric Antigen Receptor (CAR) modified T-cell therapy for the remedy of B-cell leukaemia, making Thailand the first nation in the ASEAN area to adopt this advanced medical method.
Banjong Mahaisawariya, President of Mahidol University, noted that the university’s ability to implement a therapy at present used for sure blood cancers came as a outcome of a strategic policy to advertise integration between numerous departments, reviews Bangkok Post.
CAR remedy is considered one of the few therapy options for sufferers with B-cell leukaemia, which is usually more proof against chemotherapy when compared to other types of most cancers. Banjong expressed hope that the development of this therapy domestically would considerably scale back the financial burden of therapy, as importing it from overseas is quite expensive.
“This success might be key to the future of Thai medication,” Banjong mentioned.
Piyamitr Sritara, dean of the Faculty of Medicine at Ramathibodi Hospital, revealed that the college collaborated with different institutes, state agencies, and the personal sector to trial CAR-T cell research and manufacturing in compliance with European Medicines Agency requirements.
“ Thought-provoking is now being reviewed by the Food and Drug Administration (FDA) in preparation for an utility for international certification,” Sritara added.
The venture has garnered support from the Institute for Technology and Innovation Management, the National Science and Technology Development Agency, the Health Systems Research Institute, the Program Management Unit Competitiveness, the Office of National Higher Education Science Research and Innovation Policy Council, and Rama Foundation and Genepeutic Bio Co Ltd.
Suradej Hongeng, a paediatrics lecturer at Ramathibodi Hospital, explained that research on this treatment started in 2014, with the therapy first examined on ten B-cell leukaemia patients who displayed positive outcomes.
Regarding the manufacturing process, Hongeng stated that researchers collect white blood cells from patients or their relatives, then tradition and genetically modify them within the laboratory for approximately two to a few weeks before providing the therapy to sufferers.
In some cases, it was reported that abnormalities in white blood cells vanished from blood and bone marrow within a two to four-week timeframe..